Hims & Hers Health said Saturday that it would no longer offer a compounded pill version of the popular weight-loss medicine Wegovy, following increased scrutiny from federal regulators.

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved by the agency. Last week, Hims & Hers announced ...

Hims & Hers (HIMS) pulled its semaglutide pill after legal threats from Novo Nordisk and the FDA. Hims shares plunged 22%. Hims Q3 revenue jumped 49% to $599M despite regulatory pressure. Subscriber ...

Hims & Hers Health announced it will sell Ozempic lookalike pills for $49 a month last week. The FDA objected Friday, and Novo Nordisk sued for patent infringement this morning. Novo wasn't at happy ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursuing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. But the reaction to the move has caused the ...

from Hims & Hers is giving some medical experts pause. In addition to touting the company’s weight loss drugs and testosterone treatments, it promotes a controversial early cancer detection test.

Following threats from the Food and Drug Administration (FDA) that it would take "decisive" action against companies selling "illegal copycat drugs," telehealth company Hims & Hers announced it would ...